Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vraylar
Pharma
AbbVie shrugs off new J&J competition for fast-growing Skyrizi
Immunology med Skyrizi charted sales growth of 30.9% over 2026's quarter, bringing home $4.48 billion as AbbVie's top earner.
Zoey Becker
Apr 29, 2026 2:53pm
AbbVie will continue to pursue external innovation for long-term
Jul 31, 2025 11:44am
The top 10 pharma drug ad spenders of 2024
Jun 30, 2025 3:00am
Intra-Cellular closing in on major depression nod for Caplyta
Jun 18, 2024 11:40am
The top 10 pharma drug ad spenders for 2023
Jun 3, 2024 3:00am
AbbVie to tap Vraylar messaging lessons for Cerevel drug
Dec 8, 2023 6:07am
